2-(3-aminopropyl)-2-phenyl-1,3-dioxolane | 3239-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-aminopropyl)-2-phenyl-1,3-dioxolane
• 英文别名: 3-(2-phenyl-[1,3]dioxolan-2-yl)-propylamine；3-(2-phenyl-1,3-dioxolan-2-yl)propan-1-amine
• CAS: 3239-88-1
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: XENYOWZWBBQYDA-UHFFFAOYSA-N

物化性质

• 沸点：
  110-111 °C(Press: 0.1 Torr)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-aminopropyl)-2-phenyl-1,3-dioxolane 在 盐酸 、 水 作用下， 以 吡啶 、 乙醇 为溶剂， 反应 22.5h， 生成 2-(3-benzoylpropylamino)-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone dihydrochloride
  参考文献：
  名称：

  Non-basic histamine H1-antagonists. I. Synthesis and biological evaluation of some substituted 2-(2-pyridylaminoalkylamino) pyrimidones and related compounds

  摘要：

  DOI：

  10.1016/0223-5234(89)90006-8
• 作为产物：
  描述：

  2-(3-Phthalimidopropyl)-2-phenyldioxolane 在 silica gel 、 二氯甲烷 、 氨 、 甲醇 作用下， 以 甲胺 、 甲醇 为溶剂， 反应 3.0h， 以to give the title compound as an oil (11 g, 47%)的产率得到2-(3-aminopropyl)-2-phenyl-1,3-dioxolane
  参考文献：
  名称：

  6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists

  摘要：

  本发明提供了式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：式(I)其中：R6选择自(a、b、c、d、e)和其他取代基如规范中所定义。

  公开号：

  US07981882B2

文献信息

• 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080214520A1

  公开（公告）日：2008-09-04

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R 6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

  本发明提供了Formula I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：Formula (I)其中：R6选自(a、b、c、d、e)等基团组成的群，其他取代基如规范中定义。
• PPAR-activating compound and pharmaceutical composition comprising the compound
  申请人：Yamazaki Yukiyoshi

  公开号：US20060189667A1

  公开（公告）日：2006-08-24

  A compound represented by the following formula (1): (wherein each of R 1 and R 2 , which may be identical to or different from each other, represents a hydrogen atom, a methyl group, or an ethyl group; each of R 3a , R 3b , R 4a , and R 4b , which may be identical to or different from each other, represents a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a C 1-4 alkyl group, a trifluoromethyl group, a C 1-4 alkoxy group, a C 1-4 alkylcarbonyloxy group, a di-C 1-4 alkylamino group, a C 1-4 alkylsulfonyloxy group, a C 1-4 alkylsulfonyl group, a C 1-4 alkylsulfinyl group, or a C 1-4 alkylthio group, or R 3a and R 3b , or R 4a and R 4b may be linked together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R 5 (R 5 represents a hydrogen atom, a C 1-4 alkyl group, a C 1-4 alkylsulfonyl group, or a C 1-4 alkyloxycarbonyl group); Y represents an oxygen atom, S(O) l (l is a number of 0 to 2), a carbonyl group, a carbonylamino group, an aminocarbonyl group, a sulfonylamino group, or an aminosulfonyl group; Z represents CH or N; n is a number of 1 to 6; and m is a number of 2 to 6) or a salt thereof; and therapeutic drugs containing any of such a compound or salt.

  以下式子（1）所代表的化合物：（其中R1和R2各自代表氢原子、甲基基团或乙基基团，可相同可不同；R3a、R3b、R4a和R4b各自代表氢原子、卤素原子、硝基基团、羟基基团、C1-4烷基基团、三氟甲基基团、C1-4烷氧基基团、C1-4烷基羰酰氧基团、二C1-4烷基氨基基团、C1-4烷基磺酰氧基团、C1-4烷基磺酰基基团、C1-4烷基亚磺酰基基团或C1-4烷基硫基基团，或R3a和R3b，或R4a和R4b可以连接在一起形成烷二氧基基团；X代表氧原子、硫原子或N—R5（R5代表氢原子、C1-4烷基基团、C1-4烷基磺酰基基团或C1-4烷氧基羰酰基团）；Y代表氧原子、S（O）l（l为0至2的数字）、羰基基团、羰基氨基基团、氨基羰基基团、磺酰氨基基团或氨基磺酰基基团；Z代表CH或N；n为1至6的数字；m为2至6的数字）或其盐；以及含有任何此类化合物或盐的治疗药物。
• PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Kowa Co., Ltd.

  公开号：EP1661890A1

  公开（公告）日：2006-05-31

  A compound represented by the following formula (1): (wherein each of R1 and R2, which may be identical to or different from each other, represents a hydrogen atom, a methyl group, or an ethyl group; each of R3a, R3b, R4a, and R4b, which may be identical to or different from each other, represents a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a C1-4 alkyl group, a trifluoromethyl group, a C1-4 alkoxy group, a C1-4 alkylcarbonyloxy group, a di-C1-4 alkylamino group, a C1-4 alkylsulfonyloxy group, a C1-4 alkylsulfonyl group, a C1-4 alkylsulfinyl group, or a C1-4 alkylthio group, or R3a and R3b, or R4a and R4b may be linked together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N-R5 (R5 represents a hydrogen atom, a C1-4 alkyl group, a C1-4 alkylsulfonyl group, or a C1-4 alkyloxycarbonyl group); Y represents an oxygen atom, S(O)1 (1 is a number of 0 to 2), a carbonyl group, a carbonylamino group, an aminocarbonyl group, a sulfonylamino group, or an aminosulfonyl group; Z represents CH or N; n is a number of 1 to 6; and m is a number of 2 to 6) or a salt thereof; and therapeutic drugs containing any of such a compound or salt.

  下式(1)所代表的化合物： (其中 R1 和 R2（可以相互相同或不同）各自代表氢原子、甲基或乙基；R3a、R3b、R4a 和 R4b 各自代表氢原子、卤素原子、硝基、羟基、C1-4 烷基、三氟甲基、C1-4 烷氧基、C1-4烷基碳酰氧基、二-C1-4烷基氨基、C1-4烷基磺酰氧基、C1-4烷基磺酰基、C1-4烷基亚磺酰基或C1-4烷硫基，或 R3a 和 R3b 或 R4a 和 R4b 可连接在一起形成烷二氧基；X 代表氧原子、硫原子或 N-R5（R5 代表氢原子、C1-4 烷基、C1-4 烷磺酰基或 C1-4 烷氧羰基）；Y 代表氧原子、S(O)1（1 的数目为 0 至 2）、羰基、羰氨基、氨基羰基、磺酰氨基或氨基磺酰基；Z 代表 CH 或 N；n 的数目为 1 至 6；m 的数目为 2 至 6）或其盐；以及含有任何此类化合物或盐的治疗药物。
• 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1924578B1

  公开（公告）日：2013-11-06
• US7183295B2
  申请人：——

  公开号：US7183295B2

  公开（公告）日：2007-02-27